drugset
drugset / Trial / NCT03284177

A Trial of C13-CAC Breath Test in PPI Resistant GERD Patients

NCT03284177 ↗

Phase 2 Completed 55 enrolled Otsuka Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelDiagnostic

Summary

To investigate the safety of C13-CAC and the relationship among C13-CAC breath test, gastric pH, and the improvement of symptoms by switching PPI in PPI resistant GERD patients

Timeline

Start
2017-10-31
Primary completion
2018-12-04
Completion
2018-12-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcium (13C)Carbonate Diagnostic / imaging agent — —

Indications

gastroesophageal reflux disease